The impact of the improvement of insomnia on blood pressure in hypertensive patients.

This study investigated the impact of the improvement of insomnia on the blood pressure levels of hypertensive patients. A total of 402 patients with a diagnosis of insomnia and hypertension were selected and randomly divided into two groups. The treatment group (202 cases) received standard anti-hypertensive treatment with Estazolam, and the control group (200 cases) received standard anti-hypertensive treatment with placebo. The sedentary diastolic and systolic blood pressures were measured before the treatment and every 7 days during the experiment. To assess the sleep quality and anxiety and depression levels of patients, the scores of the Pittsburgh Sleep Quality Index, the Hamilton Anxiety Rating Scale and the Hamilton Depression Scale-17 were reported at the same time points. At the conclusion of the experiment, the Pittsburgh Sleep Quality Index, Hamilton Anxiety Rating Scale and Hamilton Depression Scale-17 scores of the treatment group were significantly lower than those of the control group (P < 0.001). The insomnia treatment efficacy of Estazolam in the treatment group was 67.3%, significantly higher than that (14.0%) of the control (P < 0.001). The blood pressure of the treatment group showed significant improvement throughout the experiment. By Day 28, the decrease of sedentary diastolic and systolic blood pressures in the treatment group was significantly greater than that of the control (sedentary systolic blood pressure: 10.5 ± 3.9 versus 3.4 ± 2.5 mmHg; sedentary diastolic blood pressure: 8.1 ± 3.6 versus 2.7 ± 2.1 mmHg, P < 0.001), and the compliance rate of goal blood pressure (< 140/90 mmHg) was 74.8% with Estazolam, compared with 50.5% with placebo (P < 0.001). Thus, the current findings indicated that the improvement of insomnia can significantly help lower blood pressure in hypertensive patients.

RCT Entities:   Population Interventions Outcomes